Occurrence and Severity of DLI associated Chronic GVHD Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for acute leukemia. However, post-transplantation relapse remains one of the most important causes of transplant failure. Donor lymphocyte infusion (DLI), which aims to induce a graft-versus-leukemia (GVL) effect, is the most important immunotherapy for relapse after HSCT [1 –4]. We also reported that chemotherapy plus DLI (Chemo-DLI) can significantly improve the outcomes of patients who relapsed after allo-HSCT compared with those received chemotherapy alone [5,6].

Source: Biology of Blood and Marrow Transplantation - November 25, 2018 Category: Hematology Authors: Wen-Jing Yu, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang Source Type: research